Literature DB >> 25597633

Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer.

Muralidharan Anbalagan1, Brian G Rowan2.   

Abstract

Estrogen receptor α (ERα) is a member of the nuclear receptor superfamily of transcription factors that regulates cell proliferation, differentiation and homeostasis in various tissues. Sustained exposure to estrogen/estradiol (E2) increases the risk of breast, endometrial and ovarian cancers. ERα function is also regulated by phosphorylation through various kinase signaling pathways that will impact various ERα functions including chromatin interaction, coregulator recruitment and gene expression, as well impact breast tumor growth/morphology and breast cancer patient response to endocrine therapy. However, many of the previously characterized ERα phosphorylation sites do not fully explain the impact of receptor phosphorylation on ERα function. This review discusses work from our laboratory toward understanding a role of ERα site-specific phosphorylation in ERα function and breast cancer. The key findings discussed in this review are: (1) the effect of site specific ERα phosphorylation on temporal recruitment of ERα and unique coactivator complexes to specific genes; (2) the impact of stable disruption of ERα S118 and S167 phosphorylation in breast cancer cells on eliciting unique gene expression profiles that culminate in significant effects on breast cancer growth/morphology/migration/invasion; (3) the Src kinase signaling pathway that impacts ERα phosphorylation to alter ERα function; and (4) circadian disruption by light exposure at night leading to elevated ERK1/2 and Src kinase and phosphorylation of ERα, concomitant with tamoxifen resistance in breast tumor models. Results from these studies demonstrate that even changes to single ERα phosphorylation sites can have a profound impact on ERα function in breast cancer. Future work will extend beyond single site phosphorylation analysis toward identification of specific patterns/profiles of ERα phosphorylation under different physiological/pharmacological conditions to understand how common phosphorylation profiles in breast cancer program specific physiological endpoints such as growth, apoptosis, migration/invasion, and endocrine therapy response.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Circadian disruption; Coregulators; Estrogen receptor; Phosphorylation; Src kinase

Mesh:

Substances:

Year:  2015        PMID: 25597633     DOI: 10.1016/j.mce.2015.01.016

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  57 in total

Review 1.  Estrogens regulate life and death in mitochondria.

Authors:  Carolyn M Klinge
Journal:  J Bioenerg Biomembr       Date:  2017-08       Impact factor: 2.945

2.  Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes.

Authors:  Shanhang Jia; Mark T Miedel; Marilyn Ngo; Ryan Hessenius; Ning Chen; Peilu Wang; Amir Bahreini; Zheqi Li; Zhijie Ding; Tong Ying Shun; Daniel M Zuckerman; D Lansing Taylor; Shannon L Puhalla; Adrian V Lee; Steffi Oesterreich; Andrew M Stern
Journal:  Oncology       Date:  2018-01-06       Impact factor: 2.935

3.  The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies.

Authors:  Berry Button; Sarah Croessmann; David Chu; D Marc Rosen; Daniel J Zabransky; W Brian Dalton; Karen Cravero; Kelly Kyker-Snowman; Ian Waters; Swathi Karthikeyan; Eric S Christenson; Josh Donaldson; Tasha Hunter; Lauren Dennison; Cody Ramin; Betty May; Richard Roden; Dana Petry; Deborah K Armstrong; Kala Visvanathan; Ben Ho Park
Journal:  Breast Cancer Res Treat       Date:  2018-12-17       Impact factor: 4.872

4.  Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition.

Authors:  Kari L Ring; Melinda S Yates; Rosemarie Schmandt; Michaela Onstad; Qian Zhang; Joseph Celestino; Suet-Ying Kwan; Karen H Lu
Journal:  Int J Gynecol Cancer       Date:  2017-06       Impact factor: 3.437

5.  miR-148a Suppresses estrogen-induced viability and migration of breast cancer cells via inhibition of estrogen receptor α expression.

Authors:  Fang Ma; Yeqian Feng; Weihui Li; Zexuan Li; Tiebang Liu; Lingjiang Li
Journal:  Exp Ther Med       Date:  2017-03-22       Impact factor: 2.447

6.  Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel.

Authors:  Ying Jin; Wenquan Hu; Tong Liu; Ujala Rana; Irene Aguilera-Barrantes; Amanda Kong; Suresh N Kumar; Bei Wang; Pin Gao; Xiang Wang; Yajun Duan; Aiping Shi; Dong Song; Ming Yang; Sijie Li; Bing Han; Gang Zhao; Zhimin Fan; Qing Robert Miao
Journal:  Cancer Lett       Date:  2018-02-02       Impact factor: 8.679

7.  Activation of estrogen receptor α by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells.

Authors:  Sohei Matsumura; Tsuyoshi Ohta; Keiko Yamanouchi; Zhiyang Liu; Takeshi Sudo; Takanobu Kojimahara; Manabu Seino; Megumi Narumi; Seiji Tsutsumi; Toshifumi Takahashi; Kazuhiro Takahashi; Hirohisa Kurachi; Satoru Nagase
Journal:  Cancer Biol Ther       Date:  2016-09-30       Impact factor: 4.742

8.  Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer.

Authors:  Ze-Yi Zheng; Meenakshi Anurag; Jonathan T Lei; Jin Cao; Purba Singh; Jianheng Peng; Hilda Kennedy; Nhu-Chau Nguyen; Yue Chen; Philip Lavere; Jing Li; Xin-Hui Du; Burcu Cakar; Wei Song; Beom-Jun Kim; Jiejun Shi; Sinem Seker; Doug W Chan; Guo-Qiang Zhao; Xi Chen; Kimberly C Banks; Richard B Lanman; Maryam Nemati Shafaee; Xiang H-F Zhang; Suhas Vasaikar; Bing Zhang; Susan G Hilsenbeck; Wei Li; Charles E Foulds; Matthew J Ellis; Eric C Chang
Journal:  Cancer Cell       Date:  2020-03-05       Impact factor: 31.743

Review 9.  Endocrine resistance in breast cancer--An overview and update.

Authors:  Robert Clarke; John J Tyson; J Michael Dixon
Journal:  Mol Cell Endocrinol       Date:  2015-10-09       Impact factor: 4.102

10.  Microenvironment and endocrine resistance in breast cancer: Friend or foe?

Authors:  Sol Recouvreux; Rocío Sampayo; María Inés Díaz Bessone; Marina Simian
Journal:  World J Clin Oncol       Date:  2015-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.